Robert Goldsby, MD

Honors and Awards
  • Exceptional Physician Award, UCSF Medical Center, 2013
  1. What Are Risk Factors for and Outcomes of Late Amputation After Treatment for Lower Extremity Sarcoma: A Childhood Cancer Survivor Study Report.
  2. Survival of Patients With Primary Osseous Malignancies of the Mobile Spine Is Associated With Access to "Standard Treatment" Protocols.
  3. Day-to-Day Decision Making by Adolescents and Young Adults with Cancer.
  4. P76. An analysis of prognostic factors for patients with primary osseous malignancies of the mobile spine in the California Cancer Registry, 1988-2016.
  5. Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.
  6. Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016.
  7. 3 Dimensions of Treatment Decision Making in Adolescents and Young Adults With Cancer.
  8. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy.
  9. Frequency of face touching with and without a mask in pediatric hematology/oncology health care professionals.
  10. A portable survivorship care plan: a tool that helps educate and improve knowledge in childhood cancer survivors.
  11. Insurance impacts survival for children, adolescents, and young adults with bone and soft tissue sarcomas.
  12. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
  13. Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas.
  14. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
  15. Treatment Decision-Making Involvement in Adolescents and Young Adults With Cancer.
  16. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
  17. Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
  18. Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.
  19. Late Effects of Treatment and Palliative Care.
  20. Pocket Reference Card Improves Pediatric Resident Comfort in Caring for Children at End of Life.
  21. Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.
  22. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
  23. Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.
  25. Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor.
  26. Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma.
  27. Multiple Scalp Lesions in a Patient with Keratitis, Ichthyosis and Deafness Syndrome Mimicking Metastatic Squamous Cell Carcinoma on 18F-FDG PET/CT.
  28. Increased risk of second malignant neoplasms in adolescents and young adults with cancer.
  29. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.
  30. Recurrent stroke in childhood cancer survivors.
  31. Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
  32. Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age.
  33. Intestinal obstruction in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
  34. Second malignant neoplasms among children, adolescents and young adults with Wilms tumor.
  35. Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma.
  36. Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma.
  37. Clinical features, outcomes, and prognostic factors in patients with extraskeletal osteosarcoma.
  38. Adolescent and young adult oncology, version 2.2014.
  39. Pulmonary coccidiomycosis masquerading as refractory metastatic Ewing sarcoma.
  40. Comparison of Latino and non-Latino patients with Ewing sarcoma.
  41. Adverse impact of regional lymph node involvement in osteosarcoma.
  42. Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study.
  43. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
  44. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis.
  45. Adolescent and young adult oncology. Clinical practice guidelines in oncology.
  46. Clinical features and outcomes in patients with secondary Ewing sarcoma.
  47. Evaluation of plasma annexin V levels in children and young adults with solid tumors.
  48. CNS demyelination in fibrodysplasia ossificans progressiva.
  49. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG).
  50. Abstract 8: Radiation and modifiable Stroke Risk Factors in adult Survivors of Pediatric Cancer: Results from the Childhood Cancer Survivor Study.
  51. Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement.
  52. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma.
  53. Differentiation of normal thymus from anterior mediastinal lymphoma and lymphoma recurrence at pediatric PET/CT.
  54. Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.
  55. Survivors of childhood cancer have increased risk of gastrointestinal complications later in life.
  56. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.
  57. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma.
  58. Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation.
  59. Patellar metastatic melanoma in a 13-year-old boy.
  60. Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablation.
  61. Osteosarcoma in children 5 years of age or younger at initial diagnosis.
  62. Polymerase delta and epsilon proofreading cooperate with MMR to suppress lethal mutations and cancer in mice.
  63. Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging.
  64. Ethnic and racial differences in patients with Ewing sarcoma.
  65. Late Effects of Treatment and Palliative Care.
  66. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  67. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice.
  68. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
  69. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.
  70. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort.
  71. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors.
  72. Meta[131I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma.
  73. Alcohol consumption patterns and risk factors among childhood cancer survivors compared to siblings and general population peers.
  74. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician.
  75. Receptor imaging of pediatric tumors: clinical practice and new developments.
  76. Fibrodysplasia ossificans progressiva.
  77. PET/CT Staging und Restaging maligner Tumore bei Kindern und Jugendlichen.
  78. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.
  79. Successful Treatment of Pediatric Desmoids Using Radiation as a Component of Multimodality Therapy.
  80. Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis.
  81. Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer: a report from the Children's Oncology Group.
  82. Immunotherapy for severe aplastic anemia following orthotopic liver transplantation in children.
  83. Effect of chemotherapy on initial compressive osseointegration of tumor endoprostheses.
  84. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
  85. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
  86. Survival after recurrence of osteosarcoma: a 20-year experience at a single institution.
  87. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
  88. Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980.
  89. Surviving childhood cancer: the impact on life.
  90. Oncologic approaches to pediatric limb preservation.
  91. Pediatric malignancies. Case 2. Peripheral T-cell lymphoma in an adolescent with unsuspected Gaucher disease.
  92. Ewing sarcoma as a second malignant neoplasm after acute lymphoblastic leukemia.
  93. A phase II study of 131 I-MIBG for refractory neuroblastoma.
  94. Temozolomide and intravenous irinotecan for refractory Ewing’s sarcoma: A retrospective review.
  95. Seeding of osteosarcoma in the biopsy tract of a patient with multifocal osteosarcoma.
  96. Chapter 162 Leukemias.
  97. Chapter 163 Lymphomas.
  98. Surviving childhood cancer; now what? Controversies regarding long-term follow-up.
  99. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
  100. Neuroblastoma: evolving therapies for a disease with many faces.
  101. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
  102. Ig gene somatic hypermutation in mice defective for DNA polymerase delta proofreading.
  103. Dapsone therapy for children with immune thrombocytopenic purpura.
  104. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification.
  105. Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura.
  106. High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading.
  107. Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
  108. Defective DNA polymerase-delta proofreading causes cancer susceptibility in mice.
  109. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity.
  110. Lymphoblastic lymphoma and excessive toxicity from chemotherapy: an unusual presentation for Fanconi anemia.
  111. The molecular biology of pediatric lymphomas.
  112. Spindle cell sarcoma of the kidney with ganglionic elements (malignant ectomesenchymoma) associated with chromosomal abnormalities and a review of the literature.
  113. Mouse DNA polymerase delta gene (Pold1) maps to chromosome 7.
  114. Mouse DNA polymerase epsilon gene (Pole) maps to chromosome 5.
  115. Lymphoblast morphology in predicting leukemic meningeal relapse with low chamber count and lymphoblasts.
  116. Pediatric pulmonary artery thromboembolism: an illustrative case.